Recap: ACADIA Pharmaceuticals Q4 Earnings
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported Q4 earnings with an EPS of $0.28, missing estimates by -7%, but showed a revenue increase of $94.55 million year-over-year. Despite the miss, past performance indicates potential for share price recovery.
February 27, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ACADIA Pharmaceuticals reported a Q4 EPS of $0.28, missing estimates by -7%, with a significant year-over-year revenue increase. Historical data shows resilience in share price post-earnings.
Although ACADIA Pharmaceuticals missed EPS estimates for Q4, the increase in revenue and historical performance following earnings reports suggest a neutral to potentially positive short-term impact on the stock price. The company's ability to exceed revenue expectations and past resilience in share price post-earnings miss indicates a balanced outlook.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100